




CDEX Inc.
INNOVATIONS FOR A SAFER WORLD

Investor Presentation
January 2009



Cautionary language



This presentation includes “forward-looking statements” as defined by the Securities and Exchange Commission. These statements generally concern our plans, expectations and objectives for future operations.


All statements, other than statements of historical facts, included in the presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. They are based on assumptions which we believe are reasonable based on current expectations and projections about future events, industry conditions and trends affecting our business.

However, whether actual results and developments will conform to our expectations and predictions is subject to a number of risks and uncertainties which could cause actual results to differ materially from those contained in the forward-looking statements. CDEX has no obligation to update such forward looking statements.

Please refer to cautionary language provided in our SEC Form 10-K and Form 10-Q filings and other public disclosures.



Overview



Who we are



We are a technology development company headquartered in Tucson, AZ, specializing in advanced chemical detection.

We aim to make the world safer through our innovations.

Our vision drives us to:

- Introduce state-of-the-art products to the marketplace
- Create a growing demand for our patented technologies
- Increase our scientific knowledge and expertise to expand our future products, services and markets
- Reward our investors through a thriving, profitable and growing business enterprise
- Conduct business in a manner consistent with the fundamental beliefs of our management team

Why we will succeed



CDEX possesses the assets of success:

PEOPLE

- Skilled, inventive, resourceful, dedicated
- Our core values direct our efforts

TECHNOLOGY

- Patent-protected systems and technologies
- Intellectual property beyond current applications

PRODUCTS

- Designed to address significant problems with little competition
- Clients and distributors are world class companies
- Greater than 50% gross margins

VISION

- We are driven by our vision to protect people, save lives and make the world safer.

Innovations for a safer world



We are a global leader in Enhanced Photoemission Spectroscopy.
Our patented technologies are applied in chemical detection processes.

Our first products deal with:

- Medication and drug validation
- Illicit drug detection

We expect our proprietary systems to be applied in other fields and markets, currently including:

- Homeland security – including customs and border patrol (explosives and hazardous chemical detection)
- Brand protection and counterfeit drug identification

Superior CDEX products create market demand



Our patented technologies create unique and commanding products for many industries and markets:

- Real-time chemical detection and medication validation capabilities
- High reliability and accuracy in measurements
- Our process is lower in cost to customers compared to other technologies.
- We are building a substantial chemical/medication signature library so that our systems can serve multiple uses.
- Substance testing for security uses is non-intrusive and non-destructive:
 - Samples and evidence are preserved, not destroyed or altered.
- Our systems reduce potential errors in human interpretation.
- Competing or alternative technologies require frequent calibration and cleaning, resulting in down-time and lost productivity.

Strategy and long-term goals



We possess intellectual property and proprietary processes with many potential commercial applications.

In the future, we expect to:

- Continue the global market expansion of our existing product lines in the healthcare and security markets
- Expand our exiting product lines to price point to additional market segments
- Differentiate and distinguish our products in the market due to their reliable, accurate, ease-of-use, quick, flexible and low-cost nature
- Enhance our products and technologies with periodic updates and refinements to improve their uses
- Develop new applications using our existing technologies
- Develop or purchase additional technologies for development, and
- Exploit our competitive advantage with multiple products in multiple markets

Strategy and long-term goals



This year, we have transformed from a scientific R&D Company to full-scale manufacturing, commercial and marketing operations.

As we ramp up and expand our capabilities, over time we expect to:

- Increase the economies of scale of our business operations
- Maintain our product sales margins, which currently are above 50%
- Improve our overhead costs (selling, general and administrative) on a per-unit basis or as a percentage of revenue
- Continue investing in R&D and patent applications based on discovery and opportunity
- Continue advancing our vision and global outreach to make our world safer

Recent events




We are a Company on the move.

In recent months, among our public announcements were:

- Record year over year revenues for FYs 2007 and 2008
- Record sales/leases of ValiMed™ units in FY08
- Security Division's introduction of ID² Meth Scanner™ and Narcolyzer™ product lines
- Expansion of U.S. and international sales and marketing network, and product shipments both domestic and abroad
- TUV certification for our ValiMed medical product line (TUV Rheindland of North America testing for European standards for product safety and regulatory compliance)
- Expansion of Medication Signature Library used in ValiMed systems
- Company staff restructuring to accommodate growth:
 - We established two divisions, Medication Safety and Security, to strategically focus operations to specific market opportunity



Medication Safety Division



Medication Safety Division



We are dedicated to make healthcare settings safer by creating solutions that eliminate errors in medication formulation and dosage.

Under the **ValiMed™** brand, we offer products and services that authenticate medicines quickly, easily and economically, thereby preventing costly mistakes from harming patients.

- In FY08, we doubled the number of hospital clients using ValiMed.
- In Q4 08, we sold or leased 11 units.
- We expect to sell or lease at least 25 units in the first half of 2009.



The ValiMed™ System




We have received critical acclaim in reviews and thorough trials:

- Independent testing and analysis confirms system capabilities demonstrated by our R&D team.
- TUV certification also confirms the safety, accuracy and reliability of our systems.

A growing Medication Signature Library makes the system all the more valuable:

- Our technology has broad appeal across the medical safety field
- This library has proprietary and economic value to us, as we work with individual companies on creating unique signatures for their exclusive use.



The ValiMed™ CCT



The CCT unit is the newest ValiMed model with additional features, a smaller footprint and greater sensitivity.

- It has a full complement of validation capabilities with more features than original ValiMed unit.
- It is compatible with ValiMed software and utilizes similar components.
- This product has been introduced to both the US and international markets.



Examples of ValiMed™ market size and potential



HOSPITALS	Approximate Number
● U.S. and Canada	7,000
● Europe	10,000
● Middle East	1,000
● Asia	3,500
● Japan	9,000
● Australia/New Zealand/Oceania	2,000
Total	32,500

OTHER MARKETS
● Nursing homes
● Long-term health care facilities

Medication Safety Division expansion plans



We have a growing affiliation with sales and marketing representatives including an office in Paris, France, serving Europe and the Mid-East:


- United States
- North America
- France
- Italy
- Spain
- Portugal
- United Kingdom
- Kuwait
- United Arab Emirates
- Bahrain
- Qatar

We expect to add to our sales and marketing force on an ongoing basis going forward.





Security Division



Security Division

We are committed to make the public safer and more secure by creating ways to identify illicit drugs and dangerous chemicals quickly and easily.

Under the **ID²**TM brand, we offer products and services with our proprietary systems to assist law enforcement and others involved with public safety and property inspection.



The ID² Meth Scanner™

The ID²™ product line is the right tool for illegal drug detection to assist law enforcement and other professions in contact with the public and public places.

- The Meth Scanner is mobile, lightweight, hand-held, accurate and reliable in the field.
- In addition to law enforcement, we envision other markets will take advantage of ID² capabilities, including
 - Property inspection services
 - Schools, customs, border patrols and the military are other potential markets that can benefit from ID² capabilities.
- Our scientists are working on other hand-held detectors, including one capable of identifying additional illegal substances.



The ID² Narcolyzer™



The ID² Narcolyzer™ product line is the right tool for illegal drug detection to assist law enforcement, public safety and other professions.

- Introduced in October 2008 at the CopsWest Convention in Ontario, CA
- The Narcolyzer is based on the ValiMed CCT system architecture:
 - With fewer technical requirements, its price point is lower.
- For the customer, the operational cost for drug analysis is a fraction of costs of alternative chemical detection systems.



Examples of ID²™ market size and potential



PRIMARY MARKETS	Approximate Size
● U.S. law enforcement agencies	20,000
● U.S. school systems	15,000
Total domestic market size	35,000

OTHER MARKETS

- Property inspection services
(homes, apartments, hotels, buildings, autos, etc.)
 - Child protective services organizations
 - U.S. customs and border patrol
 - Jails and prisons
 - HAZMAT teams
 - Airports
 - International markets for all of the above
-

Security Division expansion plan



As our capabilities increase, we envision product line extensions:

- The Meth Scanner is our introductory illicit drug detector.
- We anticipate future models could incorporate additional drug signatures.
- The Narcolyzer demonstrates how the ValiMed™ CCT platform can be re-configured to complement the ID² product family.

Homeland security-related products could be an adjunct to the ID² line as part of our Security Division:

- Detection of chemicals used in explosives is showing significant potential at the R&D stage


Rapid expansion of our sales and marketing network is expected:

- Our domestic and international expansion plans include sales and marketing presence in many industries and market segments.



OTHER APPLICATIONS

– Brand Protection –



Brand protection is a new frontier




The patents, technology and systems successfully applied to the ID²™ and ValiMed™ product lines can be adapted to other products and markets:

- Our enhanced photoemission spectroscopy capability can be harnessed for many chemical identification purposes, including protecting brands and identifying counterfeit products.
- We can work with customers to create signatures of their proprietary products and work with them to identify counterfeit substances.
- According to the Organization of Economic Cooperation and Development, as much as 15% of the world's drug supply is counterfeit.
- We expect that the importance of brand protection will increase over time, and we believe our capability can be a leader in the detection of counterfeit substances throughout the globe.



Financial and Operational Review and Strategy



Our business plan is on track



We are methodical and deliberate in our business planning and operational execution.

Our objective is rapid expansion while prudently managing resources:

- We are focused on sustained revenue growth
 - Revenue grew over 50% in FYs 2007 and 2008
- Maintaining product sales gross margins in excess of 50%
- 2008 was our transformational year, from R&D to full-scale innovation, manufacturing and commercial operations.
- Resource allocation for expanded marketing network expected to foster continued revenue growth next year and beyond
- Additional operations and corporate staff to bolster production, order fulfillment, customer service, support, oversight and compliance functions, with efficiencies anticipated as we grow

Preparing for expansion and growth



We believe our proprietary domain will lead to new products and markets.

- Our planning includes ongoing R&D and innovation activity:
 - Additional patent applications
 - Systems and capabilities upgrades to existing product line
 - New products for new markets expected
- Anticipated new products for future introduction:
 - ID²™ scanner with advanced capabilities
 - Scanner with chemical detection for explosives
 - Custom scanning devices for counterfeit substance detection
 - Advanced product design/miniaturization
 - Advanced ValiMed™ systems with additional features and capabilities
- Scalable manufacturing capability to right-size inventory and assembly



We expect multiple revenue streams from our operations:

- Product sales
- Product leases
- Extended service contracts
- Charges for proprietary and technical services, including software, component and capabilities upgrades for existing products
- ValiMed™ Medication Signature Library
 - We currently have over 180 chemical signatures on file with more slated
 - These signatures are sold to our clients for their use
 - Custom signatures may be done for clients on a fee basis
- ValiMed™ cuvette (chemical sample holder) sales

Comment on corporate guidance and forecasts



In the future, we intend to issue earnings guidance or other operational or financial forecasts.

- We expect to analyze metrics and glean data from our commercial operations experience over time.
- This input will assist us with internal evaluations and improved decision making.
- We are focused on increasing revenues and attaining positive cash flows from operations, which we currently expect to occur in 2009.

Visit our web site for complete information




Our web site contains extensive information on our product line, technology and capabilities, along with upcoming events, public disclosures and links to other useful sites about the markets we aim to serve.

www.cdexinc.com



Investment Thesis Recap



CDEX enters exciting next stage of performance




We are a solid investment with a bright, promising future:

- 2008 was our transformational year from R&D to commercial operations.
- Our business plan has expanded its focus into manufacturing, marketing and sales while continuing our innovation and product creation efforts.
- Our financial foundation is improving with increased revenues:
 - Currently, we expect positive cash flows from operations in 2009.
- We expect to maintain product sales gross margins exceeding 50%.
- Our revenues and financial strength is expected to improve through multiple product lines and market expansions.
- Improved economies of scale expected as commercial operations expand.
- Our net operating losses incurred during the R&D stage reduce future income tax exposure.
- Our intellectual property and products are unique in the marketplace.
- We expect significant additional innovation, new product introductions and existing product enhancements in the years ahead.



Company Facts



CDEX key facts



Corporate headquarters

4555 S. Palo Verde, Suite 123
Tucson, AZ 85714
520.745.5172
www.cdexinc.com

Web site

Stock symbol

CEXI

Stock trading venue

OTCBB

Shares authorized

~100 million

Shares outstanding

~ 59 million

Inside ownership

< 25%

Current full-time employees/consultants

20-25

Year incorporated

2001

Public stock listing

2004

Fiscal year-end

October 31

State of incorporation

Nevada

Accounting firm

S.E. Clark & Co., PC
Tucson, AZ



Thank you for your interest in

 **CDEX Inc.**
INNOVATIONS FOR A SAFER WORLD

Malcolm Philips, Chairman, President & CEO

www.cdexinc.com

